The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease (AD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
250
one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
All events and physical and neurological function and score change from baseline to 24 weeks in ratings for cognitive and global function scales
Time frame: 6 mo extension study: week 24
Score change from baseline to 24 weeks on functional and behavioral scales
Time frame: week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
Costa Mesa, California, United States
Unnamed facility
Fresno, California, United States
Unnamed facility
La Jolla, California, United States
Unnamed facility
Orange, California, United States
Unnamed facility
Delray Beach, Florida, United States
Unnamed facility
Fort Lauderdale, Florida, United States
Unnamed facility
Fort Myers, Florida, United States
Unnamed facility
Hallandale, Florida, United States
...and 73 more locations